[Chemotherapy of small-cell lung cancer by a combination of teniposide, ifosfamide and carboplatin].
Thirty six SLC patients have been treated with a combination therapy of ifosfamide 2 g/m2, D1 and D2, carboplatin 300 mg/m2 D1 and teniposide 100 mg/m2 D1 to D3. All patients were younger than 70 years, 31 males, five females, ten limited diseases, 26 extended diseases (without brain metastasis) Performance status 0, 1 or 2, mean weight loss 3.7 kg. Thirty six patients were evaluable for response. We have noted three complete response and 28 partial response (objective response rate 86%). The main toxicity of this combination therapy was myelo-suppression (86% of grade 3 and 4). Twenty seven patients have relapsed, the median relapse free survival time is 310 days. The median survival of the 36 patients is 340 days, one patient is alive more than 30 months after the diagnosis. The ifosfamide-carboplatin-teniposide combination is an effective treatment in small cell lung cancer, its toxicity remains tolerable.
Moro
D
D
Service de pneumologie, CHU A-Michallon, Grenoble, France.
Orfeuvre
H
H
Nagy-Mignotte
H
H
Mousseau
M
M
Blanc-Jouvan
F
F
Schaerer
R
R
Brambilla
C
C
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013713:Teniposide / Q000008:administration & dosage; D016896:Treatment Outcome
D013713:Teniposide; D016190:Carboplatin; D007069:Ifosfamide
Chimiothérapie du cancer bronchique à petites cellules par une association de téniposide, ifosfamide et carboplatine.